Salute e Benessere

ZEISS announces OCT technology enhancements to better support growing era of…

Proven Analytics: As the largest reference database across all OCT devices in the U.S. market today, the ZEISS CIRRUS 6000 reference database now offers a comprehensive library of 870 healthy eyes, more than tripling the previous versions, with greater diversity, taking into account different optic disc sizes in addition to age. Elevating the standard of care for patients, the expanded reference database is a useful tool to facilitate individualized approaches to diagnoses and ocular health and…
PR Newswire
30/05/2024

Philips celebrates 1.9m liters of helium saved as it marks 1,111 helium-free MRI…

First to provide helium-free operations in 2018, Philips marks milestone during installation in Puerto RicoAmsterdam, the Netherlands and Bayamón, Puerto Rico – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and world leader in proven helium-free [1] MRI operations, today announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet, which took place in Puerto Rico's Vida Imaging & Breast Center (Bayamón, Puerto Rico). Beyond its...
Nasdaq GlobeNewswire
30/05/2024

Sebastian Professional to Broaden Artistic Vision and Empower Self-Expression…

"Becoming part of Sebastian Professional is a lifelong aspiration fulfilled for me. As Global Creative & Culture Director, I'm dedicated to fostering an inclusive space that celebrates individuality and creativity, fueling the aspirations of emerging talent. Our mission is to honor Sebastian Professional's legacy while reimagining its future as a trailblazing brand. Together, with our vibrant community, we'll blend tradition with innovation, sparking a global movement of self-expression…
PR Newswire
30/05/2024

SkylineDx's Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB…

CP-GEP Low-Risk patients demonstrated a melanoma specific survival of 99.7 at 5 years, while CP-GEP High-Risk patients had significantly heightened recurrence risk. The melanoma specific survival of the high-risk group was 42.2 at 5 years. CP-GEP Low-Risk patients demonstrated a melanoma specific survival of 99.7 at 5 years, while CP-GEP High-Risk patients had significantly heightened recurrence risk. The melanoma specific survival of the high-risk group was 42.2 at 5 years. Dr.Teresa...
PR Newswire
30/05/2024

Optellum showcases AI for precision lung cancer treatment at ASCO 2024

Early diagnosis offers patients curative treatment options. Unfortunately, some 30% to 60% of Stage I-II NSCLC patients will experience recurrence after surgery. Accurate prognosis of recurrence risk could enable thoracic oncology teams to optimize treatment early, for example, to tailor the extent of surgical resection and ensure neo-adjuvant and peri-operative treatments are offered to those at risk. To drug developers, it may enable risk-stratifying populations to increase treatment rates…
PR Newswire
30/05/2024

Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa

African trial could potentially support licensure of mpox vaccine in endemic countries and expansion of current regulatory approvals to include childrenCEPI has awarded USD 6.5 million in funding to support the Phase 2 clinical trial which is projected to start later in 2024COPENHAGEN, Denmark / OSLO, Norway, May 30, 2024– Bavarian Nordic A/S (OMX: BAVA) and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced a partnership to advance the development of Bavarian...
Nasdaq GlobeNewswire
30/05/2024

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website atir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for...
Nasdaq GlobeNewswire
30/05/2024

Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in…

Leverages real-world data, patient insights and a systematic process to design, operationalize and measure the effectiveness of diversity action plans in clinical trials Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced its comprehensive and integrated solution to improve the diversity and inclusion (D&I) of participants in clinical trials. Fortrea's D&I solution is designed to expand patient access to participate in...
Nasdaq GlobeNewswire
30/05/2024

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for…

Dr. Weiner, a distinguished researcher in the field of neurology and immunology, has dedicated his career to advancing our understanding of MS and pioneering novel therapeutic approaches. His groundbreaking work has significantly contributed to the development of innovative treatments, including intranasal foralumab, that have the potential to improve the lives of millions affected by this chronic autoimmune disease.“We are thrilled to see Dr. Howard Weiner recognized with the 'Giants of...
Nasdaq GlobeNewswire
30/05/2024

MolecuLight's Pioneering Fluorescence Imaging Technology Showcased in…

Key findings from the study include: Key findings from the study include: "These compelling results underscore the transformative impact of MolecuLight in burn wound management – yet another area of wound care where our technology drives change," said Anil Amlani, CEO at MolecuLight Inc. "By providing clinicians with real-time, objective data on bacterial presence, MolecuLight's fluorescence imaging technology empowers them to make more informed decisions, ultimately leading to…
PR Newswire
30/05/2024

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic…

SLE is a chronic autoimmune disease causing widespread inflammation and tissue damage in the affected organs. There are about one million SLE patients in China, ranking the first worldwide in total numbers and the second in incidence rate. Current conventional therapies include corticosteroids, antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), cytotoxic drugs and immunosuppressive/modulatory agents. However, conventional treatments are poorly tolerated over time, which affects…
PR Newswire
30/05/2024

Illusion Aligners Makes Record-Breaking Achievement with its Biggest Aligner in…

This Biggest Aligner holds impressive dimensions of 1900 mm (about 6.23 ft) in width and 1650 mm (about 5.41 ft) in height and was crafted meticulously using Taglus PETG material. This creation was carefully crafted in a diligent eight-step process, beginning with impression collection, pouring, and 3D model printing, followed by thermoforming and precise laser marking. It then underwent thorough finishing, polishing, and quality checking before being keenly packed. It was officially recorded on…
PR Newswire
30/05/2024

Ischemic Heart Disease (IHD) Drugs Market Worth USD 8.46 Billion to 2031 -…

Ischemic heart disease drug treatments focus on returning the heart's blood flow to a normal state, which is frequently impaired due to narrowed or blocked coronary arteries. The heart can work better and have fewer heart attacks with the help of some medications. Ischemic heart disease drug treatments focus on returning the heart's blood flow to a normal state, which is frequently impaired due to narrowed or blocked coronary arteries. The heart can work better and have fewer heart attacks…
PR Newswire
30/05/2024

Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034 |…

Key Takeaways from the Stuttering Market Report Key Takeaways from the Stuttering Market Report Discover which therapies are expected to grab the major stuttering market share @Stuttering Market Report Stuttering Overview Childhood-onset fluency disorder, commonly referred to as stuttering or stammering, is a prevalent speech issue influenced by various factors. It results in an interruption of smooth verbal expression, characterized by involuntary repetitions or...
PR Newswire
30/05/2024

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and…

Clinical study performed in 2022 now published in peer-reviewedNeurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum®Early onset can be expected thanks to early blood concentration of midazolam with ZEPIZURE®Low variability confirmed, a key advantage vs other forms of administration, such as intranasal Dijon, France May 30, 2024 -1030 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in...
Nasdaq GlobeNewswire
30/05/2024

Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01…

Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women's Hospital, said, "These results are extremely encouraging. They validate the potential for STS-01 to provide mild-to- moderate alopecia sufferers with a safe and effective treatment for this debilitating condition. I am also excited by the prospect of targeting total hair regrowth in this patient group." Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women's Hospital, said,"These…
PR Newswire
30/05/2024

Masan High-Tech Materials Group and Mitsubishi Materials Corporation Group…

Nyobolt is starting to scale and commercialize its operations. In July 2023, Nyobolt unveiled an EV concept with 6-minute charging time and has signed Head of Terms with two major commercial customers. There is monetary upside for Masan as Nyobolt starts to commercialize its innovative tungsten-niobium battery technology. Nyobolt is starting to scale and commercialize its operations. InJuly 2023, Nyobolt unveiled an EV concept with 6-minute charging time and has signed Head of Terms with two...
PR Newswire
30/05/2024

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the…

"We are proud to partner with Kvantify, a company that shares our passion for scientifically based technological solutions to real-world challenges. This partnership will expedite our drug development process and significantly expand our pipeline of promising drug candidates in 2024," says Martin Rose, Chief Executive Officer of Tetra Pharm Technologies. "We are proud to partner with Kvantify, a company that shares our passion for scientifically based technological solutions to…
PR Newswire
30/05/2024

Oculis Publishes Results of 2024 Annual General Meeting and Announces…

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRockOculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the...
Nasdaq GlobeNewswire
30/05/2024

NTC gives long term consistency to its ophtha portfolio with another MDR CE…

"To build a strong foundation and unleash sustainable growth in the future", states Riccardo Carbucicchio CEO of NTC, "we have proactively moved ahead already time ago and begun working towards meeting MDR requirements and obtaining CE marks renewals for our medical devices, according to the new EU regulation, before the deadlines. In this way, we have been trying and keep trying to secure our portfolio and give long term continuity to the agreements in place with our customers…
PR Newswire
30/05/2024

Vesper Bio announces completion of single ascending dose stage in trial of its…

Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement. Progranulin is a protein known to play a key role in promoting neuron survival, growth and function. People with FTD(GRN) have inherited gene mutations associated with low progranulin levels. Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement…
PR Newswire
30/05/2024

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative…

® (INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen...
Nasdaq GlobeNewswire
30/05/2024

Statement of total voting rights and shares forming the company's share capital…

Article R. 22-10-23 of the French Commercial CodeMarket : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site :www.inventivapharma.comDateNumber of Shares Outstanding Total voting rights, gross(1) Total voting rights, net(2)May 13, 202452 477 18865 493 08165 381 630 (¹) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11...
Nasdaq GlobeNewswire
30/05/2024

Combined General Meeting of June 20, 2024 - Availability of the preparatory…

Daix (France), Long Island City (New York, United States), May 30, 2024– Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined...
Nasdaq GlobeNewswire
30/05/2024
Altri  Comunicati